Published in J Virol on March 04, 2015
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition. Biomark Cancer (2016) 0.75
VSV based virotherapy in ovarian cancer: the past, the present and …future? J Cancer (2017) 0.75
Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 11.57
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis (2002) 4.23
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 4.18
Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer (2005) 3.93
Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc Natl Acad Sci U S A (2001) 2.48
Going viral with cancer immunotherapy. Nat Rev Cancer (2014) 2.27
Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest (2007) 2.26
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10
Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol (2001) 1.92
Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys (2008) 1.85
Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life (2000) 1.81
Evidence for involvement of protein kinase C in the cellular response to interferon alpha. Proc Natl Acad Sci U S A (1990) 1.77
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol (2008) 1.73
Vesicular stomatitis virus as an oncolytic vector. Viral Immunol (2004) 1.70
Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology (2004) 1.53
Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther (2005) 1.43
Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol (2005) 1.34
Preferential translation of vesicular stomatitis virus mRNAs is conferred by transcription from the viral genome. J Virol (2006) 1.18
Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells (2007) 1.14
Glycogen synthase kinase-3beta facilitates IFN-gamma-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2. J Immunol (2009) 1.13
Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J Virol (2008) 1.13
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology (2012) 1.12
Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol (2014) 1.11
Culture of mouse prostatic epithelial cells from genetically engineered mice. Prostate (2005) 1.10
Viruses for tumor therapy. Cell Host Microbe (2014) 1.09
The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res (2003) 1.08
Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J Neurovirol (2007) 1.06
Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol (2008) 1.05
Suppression of Tak1 promotes prostate tumorigenesis. Cancer Res (2012) 1.04
Oncolysis of prostate cancers induced by vesicular stomatitis virus in PTEN knockout mice. Cancer Res (2010) 1.03
The protein kinase Akt1 regulates the interferon response through phosphorylation of the transcriptional repressor EMSY. Proc Natl Acad Sci U S A (2012) 1.02
Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol (2012) 1.01
Potency of wild-type and temperature-sensitive vesicular stomatitis virus matrix protein in the inhibition of host-directed gene expression. Virology (1996) 1.00
Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy. J Virol (2013) 0.95
Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther (2012) 0.95
Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol (2011) 0.95
Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res (2014) 0.94
Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus. Cancer Gene Ther (2010) 0.91
Interaction between the androgen receptor and RNase L mediates a cross-talk between the interferon and androgen signaling pathways. J Biol Chem (2005) 0.90
Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis (2011) 0.90
Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J Virol (2013) 0.89
Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther (2011) 0.89
Regulation of SHP2 by PTEN/AKT/GSK-3β signaling facilitates IFN-γ resistance in hyperproliferating gastric cancer. Immunobiology (2012) 0.89
1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Prostate (2010) 0.88
Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. J Virol (2011) 0.87
Vesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo. Int J Interferon Cytokine Mediat Res (2010) 0.84
High-risk prostate cancer: a disease of genomic instability. Urol Oncol (2014) 0.84
Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus. Mol Ther (2013) 0.81
Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis. Mol Ther (2013) 0.80
Collagen gel culture system and analysis of estrogen effects on mammary carcinogenesis. Arch Toxicol (1984) 0.76